Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Bennett-Guerrero, 2021
 
NCT04344535
RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
59/15 inconclusive -18% -23%
COALIZAO ACTION, 2021
 
NCT04394377
RCTanticoagulant, curative dosecontrolCOVID 19 hospitalizedsome concern
311/304 inconclusive 50%
COALIZAO ACTION, 2021
 
NCT04394377
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID 19 hospitalizedsome concern
311/304 inconclusive 50%
CONCOR-1, 2021
 
NCT04348656
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
625/313 safety concern 2% 14%
Horby, 2021
 
NCT04381936
RCTcolchicinestandard of careCOVID 19 hospitalizedsome concern
5610/5730 inconclusive 1%
Kirenga, 2021
 
NCT04542941
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
67/69 inconclusive 23%
Mahajan, 2021 RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
41/41 inconclusive 21%
RCT-TCZ-COVID-19, 2021
 
NCT04346355
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
60/66 inconclusive 112%
RECOVERY, 2021
 
NCT04381936
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
2022/2094 conclusif demonstrated-13% -13%
RECOVERY (plasma), 2021
 
NCT04381936
RCTconvalescent plasma treatmentcontrolCOVID 19 hospitalizedsome concern
5795/5763 inconclusive 0% -1%
Rutgers, 2021 RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
174/180 suggested -34% -32%
Soin AS (COVINTOC), 2021
 
CTRI/2020/05/025369
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
90/90 inconclusive -30%
Abd-Elsalam, 2020
 
NCT04353336
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
97/97 inconclusive 19%
Chen, 2020
 
NCT04384380
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
21/12 inconclusive -40%
ConCOVID (Gharbharan et al.), 2020
 
NCT04342182
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
43/43 inconclusive -5%
ConPlas-19, 2020
 
NCT04345523
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
179/171 inconclusive -48% -4% -5%
Dongsheng Wang, 2020
 
ChiCTR2000029765
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
33/32 safety concern 123%
EMPACTA, 2020
 
NCT04372186
RCTtocilizumab placeboCOVID 19 hospitalizedsome concern
259/129 conclusif 12% 13% demonstrated-40%
Gonzalez_HCQ, 2020
 
NCT04391127
RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
33/37 inconclusive -60% -28%
GRECCO-19, 2020
 
NCT04326790
RCTcolchicinestandard of careCOVID 19 hospitalizedsome concern
55/50 suggested -71%
HAHPS, 2020
 
NCT04329832
RCThydroxychloroquineazithromycinCOVID 19 hospitalizedsome concern
42/43 inconclusive 540%
HYCOVID, 2020
 
NCT04325893
RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
124/123 inconclusive -41% 11%
NO COVID-19 (Lyngbakken), 2020
 
NCT04316377
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
27/26 inconclusive -4%
ORCHID, 2020
 
NCT04332991
RCThydroxychloroquineplaceboCOVID 19 hospitalizedlow
242/237 inconclusive 6% 2% 12%
RECOVERY, 2020
 
NCT04381936
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
1561/3155 safety concern 8% 13%
Salehzadeh, 2020
 
IRCT20200418047126N1
RCTcolchicineplaceboCOVID 19 hospitalizedsome concern
50/50 inconclusive 0%
Salman, 2020
 
NCT04530370
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
15/15 inconclusive
SOLIDARITY (remdesivir), 2020
 
NCT04315948
RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
2750/2725 inconclusive -5% -3%
SOLIDARITY (WHO study) HCQ, 2020
 
NCT04315948
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
947/906 inconclusive 17% 10%
TEACH, 2020
 
NCT04369742
RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
67/61 inconclusive 6%

COVID 19 all comers meta-analysis

BACC Bay Tocilizumab Trial, 2020
 
NCT04356937
RCTtocilizumab placeboCOVID 19 all comerslow
161/81 inconclusive 47% 5% -15%
NIH NIAID ACTT-1, 2020
 
NCT04280705
RCTremdesivirplaceboCOVID 19 all comerssome concern
541/521 suggested -40% 26%

COVID-19 mild to moderate meta-analysis

ATTACC, ACTIV-4a, and REMAP-CAP, noncritically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative dosecontrolCOVID-19 mild to moderatesome concern
1190/1054 conclusif -11% -16%
ATTACC, ACTIV-4a, and REMAP-CAP, noncritically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 mild to moderatesome concern
1190/1054 conclusif -11% -16%
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020
 
NCT04322123
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
221/227 safety concern 42%
GS-US-540-5774, 10 days, 2020
 
NCT04292730
RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
197/200 safety concern -22% 14%
GS-US-540-5774, 5 days, 2020
 
NCT04292730
RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
199/200 conclusif -44% demonstrated58%
HC-nCoV (Shanghai), 2020
 
NCT04261517
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
15/15 inconclusive 0%
Libster, 2020
 
NCT04479163
RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
80/80 conclusif -45%

COVID-19 severe or critically meta-analysis

CAPSID, 2021
 
NCT04433910
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
53/52 inconclusive -15% 52%
HYDRA (Hernandez-Cardenas), 2021
 
NCT04315896
RCThydroxychloroquineplaceboCOVID-19 severe or criticallysome concern
106/108 inconclusive -18%
INSPIRATION, 2021
 
NCT04486508
RCTanticoagulation, intermediate prophylactic dosecontrolCOVID-19 severe or criticallysome concern
276/286 inconclusive 8%
INSPIRATION, 2021
 
NCT04486508
RCTanticoagulation, intermediate prophylactic doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
276/286 inconclusive 8%
O’Donnell, 2021
 
NCT04359810
RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
150/73 inconclusive -48% 18%
REMAP-CAP plasma, 2021
 
NCT02735707
RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
1095/916 safety concern -4%
REMAP-CAP tocilizumab, 2021
 
NCT02735707
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
353/402 conclusif -27% demonstrated58%
REMAP-CAP, ACTIV-4a, ATTACC, critically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative dosecontrolCOVID-19 severe or criticallysome concern
591/616 inconclusive 7% -15%
REMAP-CAP, ACTIV-4a, ATTACC, critically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
591/616 inconclusive 7% -15%
Sekine (PLACOVID), 2021
 
NCT04547660
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
80/80 inconclusive 34% -5%
Talaschian, 2021
 
IRCT20081027001411N4
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive 23%
Veiga, 2021
 
NCT04403685
RCTtocilizumab controlCOVID-19 severe or criticallysome concern
65/64 safety concern safety concern153% 49%
Veiga, 2021
 
NCT04403685
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
65/64 inconclusive
AlQahtani, 2020
 
NCT04356534
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive -47%
CAP-China (Wang et al.), 2020
 
NCT04257656
RCTremdesivirplaceboCOVID-19 severe or criticallylow
158/79 inconclusive 9% 21%
CORIMUNO-19, 2020
 
NCT04331808
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
64/67 inconclusive -7% -39%
COVACTA (Rosas), 2020
 
NCT04320615
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
301/151 safety concern 25% 17%
Li, 2020
 
ChiCTR2000029757
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
52/51 inconclusive -37% 36%
PlasmAr, 2020
 
NCT04344535
RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
228/106 inconclusive -6% -17%
PlasmAr, 2020
 
NCT04344535
RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
228/106 inconclusive -6% -17%
65 studies excluded by filtering options (27 RCT / 38 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).